MedTrace Logo

A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants

NCT07479641 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-04-17

No results posted yet for this study

Summary

This study will investigate the bioequivalence between two formulations of HRS-1893 tablets. Safety and tolerability will also be assessed.

Conditions

Interventions

DRUG

Test formulation of HRS-1893 tablet

Test formulation of HRS-1893 tablet, oral.

DRUG

Reference formulation of HRS-1893 tablet

Reference formulation of HRS-1893 tablet, oral.

Sponsors & Collaborators

  • Shandong Suncadia Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-14
Primary Completion
2026-06-30
Completion
2026-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07479641 on ClinicalTrials.gov